Distinct T-cell signatures identified in children with type 1 diabetes

A study conducted at the University of Eastern Finland found distinct signatures in CD8-positive T cells in blood samples from children with newly diagnosed type 1 diabetes and in autoantibody-positive children who later developed type 1 diabetes. The study was published in the journal Diabetes.

Type 1 diabetes is an autoimmune disease which usually develops in childhood. The symptomatic onset of type 1 diabetes results from a T-cell mediated destruction of insulin-producing beta cells in the pancreas. CD4-positive helper T cells orchestrate the autoimmune response, while CD8-positive cytotoxic T cells directly contribute to the destruction of the beta cells. Interestingly, a specific blood CD8-positive T-cell signature has recently been associated with a beneficial response to immunotherapy treatments aiming to delay the onset of type 1 diabetes.

In the current study, led by Professor Tuure Kinnunen at the University of Eastern Finland, two distinct signatures were detected in a subset of circulating, highly differentiated CD8-positive T cells in children at different stages of type 1 diabetes development. A proinflammatory signature consisting of an increased frequency of T cells producing proinflammatory cytokines, such as IFN-γ and TNF-α, was detected in children with newly diagnosed type 1 diabetes. In contrast, in autoantibody-positive at-risk children who later developed type 1 diabetes, an increased frequency of T cells expressing the co-inhibitory receptors KLRG1 and TIGIT was detected. Importantly, the latter signature resembles the CD8-positive T-cell signature associated with a beneficial response to immunotherapy in earlier studies.

"Our findings suggest that before disease onset, children who later progress to clinical type 1 diabetes have a distinct CD8-positive T-cell profile detectable in their blood samples. It could be envisioned that this is a potential, but eventually failing attempt of the immune system to harness the harmful autoimmune response. In the future, these T-cell signatures could potentially be used to develop better biomarkers for evaluating the risk of developing type 1 diabetes, and who would benefit from preventative immunotherapy. Additionally, a deeper characterization of these interesting cell types is warranted to better understand the type 1 diabetes disease process", University Teacher Anna-Mari Schroderus, the lead author of the study notes.

This study utilized samples from the unique Finnish DIPP follow-up study where children with a genetic risk for the development of type 1 diabetes are followed from birth. The study also involved researchers from the universities of Turku, Oulu, and Helsinki, and Kuopio University Hospital.

Source:
Journal reference:

Schroderus, A-M., et al. (2024). Temporal Alterations in CD8+ T Cells During the Progression from Stage 1 to Stage 3 Type 1 Diabetes. Diabetes. doi.org/10.2337/db24-0159.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes drug semaglutide proves beneficial for patients with chronic kidney damage and obesity